Montrucchio Giorgia, Traversi Riccardo, Arrigo Gabriele, Bonetto Chiara, Sales Gabriele, Busca Alessandro, Fanelli Vito, Filippini Claudia, Brazzi Luca
Department of Surgical Sciences, University of Turin, Turin, Italy.
Department of Anesthesia, Intensive Care and Emergency, Anestesia e Rianimazione 1U, Città della Salute e della Scienza Hospital, Turin, Italy.
Front Med (Lausanne). 2025 Sep 8;12:1622770. doi: 10.3389/fmed.2025.1622770. eCollection 2025.
Hemophagocytic Lymphohistiocytosis (HLH) is a rare life-threatening syndrome characterized by hyperinflammation caused by abnormally activated macrophages and cytotoxic T cells overlapping with sepsis and multi-organ disfunction (MOD). Its frequency is probably underestimated.
Patients' data were extracted from a literature search performed on PubMed (MEDLINE) and EMBASE using the following search terms: "Hemophagocyitic Lymphohistiocytosis" OR "HLH" OR "MACROPHAGE ACTIVATING SYNDROME" OR "MAS" AND "Intensive Care Unit" OR "Critical Care" OR "ICU." Search was limited to articles published after 2014, when HScore was proposed.
We found 126 case reports and case series for a total of 148 patients with an overall mortality of 47.5%. Main triggers were infections (111 patients; 88.1%) followed by dysimmune disorders (29 patients; 19.7%) and hematological malignancies (20 patients; 13.6%). The following factors were associated with increased ICU mortality: viral infection (76 patients; 52.8%) = 0.0071 and = 0.0086 at multivariate analysis for SARS-CoV-2, hematological malignancies ( = 0.0035 at univariate analysis; = 0.0083 at multivariate analysis), invasive mechanical ventilation (116 patients; 83.3%) = 0.0060 at univariate analysis not confirmed in multivariate analysis ( = 0.0599). Corticosteroids were associated with reduced ICU mortality at univariate analysis (86 patients; 59.7% = 0.0250) not confirmed at multivariate analysis ( = 0.7196).
Evidence from our analysis confirms the severity and rapid evolution of HLH, suggesting the importance of prompt clinical suspicion. Since HLH can be found in different hospital settings, including ICU, we believe that this syndrome should be considered in differential diagnosis for all patients presenting with MOD with unclear etiology. Development of specific diagnostic and therapeutic schemes should be considered a priority.
噬血细胞性淋巴组织细胞增生症(HLH)是一种罕见的危及生命的综合征,其特征为异常活化的巨噬细胞和细胞毒性T细胞引起的过度炎症,与脓毒症和多器官功能障碍(MOD)重叠。其发病率可能被低估。
使用以下检索词从PubMed(MEDLINE)和EMBASE上进行的文献检索中提取患者数据:“噬血细胞性淋巴组织细胞增生症”或“HLH”或“巨噬细胞活化综合征”或“MAS”以及“重症监护病房”或“危重症护理”或“ICU”。检索限于2014年提出HScore后发表的文章。
我们共找到126篇病例报告和病例系列,涉及148例患者,总死亡率为47.5%。主要诱因是感染(111例患者;88.1%),其次是免疫失调(29例患者;19.7%)和血液系统恶性肿瘤(20例患者;13.6%)。以下因素与ICU死亡率增加相关:病毒感染(76例患者;52.8%),在SARS-CoV-2的多变量分析中P=0.0071且P=0.0086;血液系统恶性肿瘤(单变量分析中P=0.0035;多变量分析中P=0.0083);有创机械通气(116例患者;83.3%),单变量分析中P=0.0060,多变量分析未证实(P=0.0599)。皮质类固醇在单变量分析中与ICU死亡率降低相关(86例患者;59.7% P=0.0250),多变量分析未证实(P=0.7196)。
我们分析的证据证实了HLH的严重性和快速进展,提示及时临床怀疑的重要性。由于HLH可在包括ICU在内的不同医院环境中发现,我们认为对于所有病因不明的MOD患者进行鉴别诊断时应考虑该综合征。应优先考虑制定特定的诊断和治疗方案。